Valuation : Open Orphan plc

Market Cap 47.75M 64.65M 55.59M 52.33M 89.11M 6.13B 89.56M 619M 239M 3.13B 242M 237M 9.94B P/E 2026 *
-14x
P/E 2027 * -69.5x
Enterprise Value 39.26M 53.15M 45.7M 43.02M 73.26M 5.04B 73.63M 509M 197M 2.58B 199M 195M 8.17B EV / Sales 2026 *
0.78x
EV / Sales 2027 * 0.68x
Free-Float
96.84%
Yield 2026 *
0.46%
Yield 2027 * 1.19%
3 years 0.23
Extreme 0.23
0.36
5 years 0.12
Extreme 0.115
0.36
10 years 0.12
Extreme 0.115
0.5
Manager TitleAgeSince
Chief Executive Officer 57 2022-02-23
Corporate Officer/Principal 39 2017-06-30
Director of Finance/CFO 63 2022-10-17
Director TitleAgeSince
Chairman 65 2025-06-04
Director/Board Member 57 2021-10-12
Director/Board Member 63 2022-10-17
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 66.53M
-0.82%-3.57%-3.71%+12.92% 48.41B
-1.29%+0.85%+411.90%+546.06% 45.01B
-3.20%-0.76%+38.11%+18.36% 44.07B
-1.89%-2.25%+2.83%+80.93% 40.73B
-1.72%-3.07%+13.76%+43.40% 33.21B
-0.17%+2.68% - - 17.77B
-0.07%-0.52%+21.34%+117.49% 16.5B
-0.56%-1.85%+11.53%+30.40% 14.45B
-2.68%-2.60%+71.21%+37.36% 13.77B
Average -1.24%+0.20%+70.87%+110.87% 30.44B
Weighted average by Cap. -1.54%-0.12%+86.33%+131.34%

Financials

2026 *2027 *
Net sales 50.37M 68.21M 58.65M 55.2M 94.01M 6.47B 94.49M 653M 252M 3.3B 256M 250M 10.49B 55.23M 74.79M 64.3M 60.53M 103M 7.09B 104M 716M 277M 3.62B 280M 275M 11.5B
Net income -3.62M -4.9M -4.21M -3.96M -6.75M -464M -6.78M -46.9M -18.13M -237M -18.37M -17.98M -753M -1.12M -1.52M -1.3M -1.23M -2.09M -144M -2.1M -14.51M -5.61M -73.41M -5.68M -5.56M -233M
Net Debt -8.49M -11.5M -9.89M -9.31M -15.85M -1.09B -15.93M -110M -42.56M -557M -43.12M -42.22M -1.77B -9.93M -13.45M -11.56M -10.89M -18.54M -1.28B -18.63M -129M -49.79M -652M -50.44M -49.39M -2.07B
Logo Open Orphan plc
hVIVO plc is a United Kingdom-based purpose-built, full-service international clinical development partner and engaged in human challenge trials serving biopharma companies. The Company has an end-to-end platform designed to bring important medicines to patients faster: spanning preclinical strategy, first in human studies, Phase II patient trials and specialist laboratory services, delivered through a participant database, wholly owned sites and laboratories across the UK and Germany. The Company offers integrated service lines which include consulting, clinical trials, human challenge trials, and laboratories. Its consulting provides preclinical and clinical strategy, encompassing non-clinical, clinical, CMC, pharmacokinetics, data management, biostatistics, and regulatory support to guide trial design, execution, and interpretation. The Company is also focused on Phase I/II clinical studies, particularly in dermatology and women's health.
Employees
376
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
0.0695GBP
Average target price
0.1594GBP
Spread / Average Target
+129.32%

Annual profits - Rate of surprise

40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!